Samsung Biologics established a reputation as being one of the most dependable, high-quality CDMOs currently on the market, pushing innovative solutions that have left their clients satisfied with every project. Their commitment to future-centric thinking even extends to user experience with their virtual platform for engaging with clients.
What is Samsung Biologics?
Samsung Biologics is a biopharmaceutical CDMO, also known as a contract development and manufacturing organization, who works with clients to help their manufacturing and production needs. They can offer everything from fill/finish services to research and development, partnering with major organizations to get their drug product or other project across the finish line.
Samsung Biologics, part of the Samsung Group, has become one of the leading CDMOs not only thanks to their high-profile partnerships with companies like Moderna, GSK, and Lilly, but also through their ambitious expansion worldwide over the last 18 months.
The biggest project on the horizon? The construction of their massive Plant 4.
Meet the Super Plant, or Plant 4
In November 2020 in Incheon, South Korea (where Samsung Biologics keeps its headquarters), the company officially began construction on Plant 4, or the “Super Plant.” Upon completion, it will be the largest manufacturing facility for biopharmaceuticals on earth, boasting 238,000 square-meters of building space and 256,000 liters of total manufacturing capacity.
Once Plant 4 is completed and fully operational, it’s estimated that Samsung Biologics will be responsible for an astounding one-fourth of all total global bio-CMO manufacturing capacity, with their Incheon headquarters offering a combined total of 620,000 liters of manufacturing capability.
One of the most unique aspects of the plant’s design is its modular construction, which will allow for certain areas of the plant to be adapted to serve a range of needs, increasing flexibility when it comes to meeting specific orders and the parameters of certain partnerships.
Other features of the plant include multiple sizes of bioreactors ranging from 2,000 liters to 15,000 liters, full CDO, CMO, and bioanalytical and testing service capability, aseptic fill/finish capability and a full internal QC lab to ensure quality control for their own work and for clients.
Other Planned Plants & Investments for Samsung BIologics
It was also recently announced that Samsung group would invest an additional $200 billion in various projects, primarily biotech industry properties such as Samsung Biologics. This includes the production of at least two additional plants, which when completed will further enhance the CDMO’s manufacturing capacity. The future is certainly an exciting one for Samsung Biologics and the CDMO industry as a whole.